Outcome
    Limited

    Curcumin for Tumor Response Rate

    Curcumin has preclinical anticancer signals and no demonstrated effect on tumour response.

    Overview

    Curcumin has preclinical anticancer signals and no demonstrated effect on tumour response.

    Verdict

    Insufficient evidence

    How It Works

    Modulates NF-kB and multiple inflammatory and apoptotic pathways in vitro.

    Dosing & Protocol

    Typical dose

    Recommended dose
    No established dose — evidence is insufficient. Oncology trials used 2-8 g/day curcumin, or 180-500 mg/day of enhanced forms, without demonstrated tumour response.
    Expected timeframe
    No benefit demonstrated

    Protocol

    dose
    Not established
    form
    Curcumin (2-8 g/day plain, or enhanced formulations, in phase I/II oncology studies)
    steps
    Evidence is insufficient: early-phase oncology trials at 2-8 g/day have shown tolerability and some biomarker changes, but no reliable improvement in tumour response rate,Curcumin is not a cancer treatment and must never replace or delay chemotherapy, radiotherapy, surgery or immunotherapy,Curcumin can interact with chemotherapy through CYP and P-glycoprotein pathways and may reduce the effectiveness of some agents,If you want to use it during treatment, ask your oncologist first — this is a decision for the treating team, not self-management
    timing
    n/a
    duration
    Trials ran weeks to months

    Evidence

    What the studies say

    Extensive cell and animal work has not translated into human tumour response data. Bioavailability is poor and some formulations interact with chemotherapy metabolism.

    Curcumin as an adjunct in cancer therapy: systematic review of clinical trials

    Score: 5/10
    2020
    systematic_review

    Mansouri K, Rasoulpoor S, Daneshkhah A +5 more

    Curcumin adjuncts were associated with improved treatment tolerance and some improvement in response markers

    View source

    Safety

    Caveats

    Insufficient evidence. Potentially harmful interactions with chemotherapy and radiotherapy. Bleeding risk matters greatly with treatment-related low platelets. Rare hepatotoxicity, which is a concern alongside hepatotoxic chemotherapy. Never substitute for oncology care.

    Less likely to help if

    Not applicable — no tumour response benefit has been demonstrated.

    Medical Disclaimer

    The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

    Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.